A baseline study has been conducted to determine the polymorphism of reverse transcriptase, protease, and envelope genes of HIV-1 isolates from 146 antiretroviral drug-naive Cambodian patients including 22 seroconverters and 124 pregnant women having been diagnosed HIV positive for less than 1 year. Amplification of at least one gene was successful for 144 isolates. All three genes were obtained for 136 isolates. Subtyping showed that CRF01_AE was predominant (130 cases). According to the ANRS September 2004 list, polymorphism substitutions (Ͼ50% versus the subtype B consensus) of CRF01_AE at drug resistance positions were observed only in protease: I13V (81%), E35D (87%), M36I (100%), R41K (96%), and H69K (100%). Two strains bore one major resistance mutation to PIs: M46I and N88D. Five other strains carried drug resistance mutations to RTIs: K70R (one strain), V75M (three strains), and K101E (one strain). Of the isolates 4.9% had drug resistance mutations to antiretroviral drugs.
M
OLECULAR CHARACTERIZATION SHOWED THAT HIV-1 strains could be classified into three genetically distinct groups of HIV-1: M (main), O (outlier), and N (non-M non-O or New). The group M, which accounts for most infections worldwide, is further divided into at least nine distinct subtypes (A-D, F, G, H, J, K) and 16 circulating recombinant forms (CRFs) based on sequences within the gag, polymerase (pol), and envelope (env) (http://hiv-web.lanl.gov/content/hiv-db/ HelpDocs/subtypes-more.html). This extraordinary degree of genetic diversity, specially in Africa, has shown some impact on biology, such as diagnosis, infectivity, transmissibility, vaccine development, and response to antiretroviral drugs (ARVs). 1 The pattern of ARV resistance-associated mutations in subtype B is well characterized, although this subtype accounts for a small part of the global HIV pandemic and is predominant in developed countries. On the contrary, studies on non-B subtypes circulating mostly in the other countries are limited. Minor mutations of resistance in the protease are often present as natural variants in the non-B subtype and antiretroviral pressure on these subtypes may result in differences in the long-term outcome of antiretroviral therapy. 2 CRF01_AE is the predominant subtype circulating in Southeast Asia (http://www.hiv.lanl.gov/content/hiv-db/geography/ geography.comp) and its natural polymorphism has been described recently in Thailand, Vietnam, and Singapore. [3] [4] [5] [6] In Cambodia, which is the Southeast Asian country with the highest HIV-1 seroprevalence, two studies carried out in the 1990s reported the predominance of subtype E. 7, 8 The aim of our study was to further characterize the natural polymorphism of HIV-1 in the genes of the protease (prot), reverse transcriptase (rt), and C2V3 envelope (env) and to describe the prevalence of mutations involved in resistance to ARVs [nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs)] among untreated patients before the widespread use of ARVs in Cambodia supported by the World Health Organization (WHO) 3 by 5 initiative (http://www.who.int/3by5/en/countries.pdf).
From February 2003 to December 2004, two groups of consecutive patients with no history of antiretroviral therapy gave their informed consent to participate in our study approved by the National Ethical Committee of Cambodia. The first group was repeat consultants to the voluntary counseling and testing center of the Institut Pasteur du Cambodge, with a known date of seroconversion of less than 1 year. The second group was composed of pregnant women attending prenatal clinics at four sites (Calmette Hospital and The National Maternal and Child Health Center in Phnom Penh and the Serey Sophon and Poipet health centers in Beantey Mean Chey province) among the six centers in Cambodia, which applied the PMTCT program in 2003. Pregnant women were accepted in the study if they were tested HIV seropositive for the first time during the previous year and if they declared they were naive to ARVs. In total, 146 patients participated (22 from group 1 and 124 from group 2).
Blood was collected in EDTA tubes. Plasma was separated and stored at Ϫ80°C before being used for further studies. HIV-1 serology was confirmed positive at the Institut Pasteur du Cambodge with ELISA Genscreen HIV1/2 (Bio-Rad, Marnes la Coquette, France), MEIA (Abbott AXSYM System, Wiesbaden, Germany), and Western blot assay (HIV Blot 2.2, Genelabs Diagnostics Pte Ltd, Singapore). Viral RNA was extracted from plasma using QIAampViral RNA mini kit (Qiagen, Hilden, Germany), reverse transcribed to cDNA and amplified for prot, rt, and env genes using the Agence Nationale de Recherche sur le Sida (ANRS) consensus sets of primers. 9 Alternative primers were used when amplification with the ANRS primers was unsuccessful. The alternative prot primer sequences were as follows (positions in parentheses are indicated according to HXB2 sequence accession number K03455): PI-1685 5Ј-GGAATTTTCCTCA-GAGCAGACCAG (2125-2149) and PI-2209 5Ј-TCTTCT-GTCAATGGCCACTGTTTAAC (2610-2635) as outer primers, and PI-1685 and PI-2172 5Ј-CCATTCCTGGCTT-TAATGTTACTGGTAC (2572-2593) as inner primers. The rt gene fragment was amplified with the following alternative primer pairs: RT-A35TH 5Ј GGTTGTACTT-TAAATTTCCCAATTAGTCC (2532-2561) 10 and RT-2955 5Ј-GCTTTACCTTAATCCCTGCATAAAT (3358-3381) as outer primers, and RT-B887-2 5Ј-CTGTACCAGTAACAT-TAAAGCCAGG (2569-2593) 10 and RT-2923 5Ј-GCC-CAATTTAGTTTTCCCACTAAT (3326-3349) as inner primers. The fragments obtained were sequenced on both strands using Genome Express company (Meylan, France). Unverified sequences and chromatograms sent by the company were verified, analyzed, interpreted, and aligned. ClustalX 1.81 software was used for alignment sequences with subtype reference sequences set from the HIV sequence Los Alamos Database (http://hiv-web.lanl.gov/content/hivdb/SUBTYPE_REF/align.html) and for phylogenetic analysis genotypes using a nucleotide-distance matrix and the bootstrap neighbor-joining method. The presence of drug resistance-associated mutations (DRM) in the prot and rt was detected, and drug susceptibility based on subtype B was predicted from the ANRS algorithm updated in September 2004 (http://www.hivfrenchresistance.org/tab2004.html).
HIV-1 infection was serologically confirmed for all the 146 patients using Western blot assay. However, the amplifications of the three targeted genes were unsuccessful for two pregnant women. Sequences of all the three genes were obtained for 136 individuals, whereas env and/or prot sequences were missing for eight patients. The failure to amplify could be explained by unusual polymorphisms in the targeted regions inducing a primer template mismatch or by a low viral load (data not available in this study), rather than sample degradation. The phylogenetic analysis performed on the three genes for 136 patients revealed that CRF01_AE was predominant (130 patients, 95.5%) followed by subtype B, CRF15_01B, and unknown recombinant forms (two patients, 1.5% each). Phylogenic analysis performed with an uncompleted set of sequences for eight patients showed only CRF01_AE sequences. This result confirms that this subtype is predominant in Cambodia, and likewise in neighboring countries of Southeast Asia. 4, 5, 11 The amino acid substitutions of the Rt are described in Fig.  1 were shared with other consensus subtypes and none of these consensus mutations occurred in an important site of the Rt protein (Fig. 2) . The deduced CRF01_AE Cambodian natural consensus (Ͼ50%) was in agreement with the CRF01_AE consensus observed among Southeast Asian untreated patients and described in previous studies. [3] [4] [5] Differences between theses consensus were very few. The Thai and the Singaporean consensus differed from the Cambodian and the Vietnamese consensus at position 43. The Singaporean consensus had no mutation at position 178 while only the Vietnamese consensus had mutations at positions 162 and 230 (Fig. 2) . These mutations could constitute hallmarks of the CRF01-AE strains predominant in these countries. In our study mutation K43E occurred for 56 (40%) of the 140 CRF01_AE strains (Fig. 1 ) and the codon 43 is one of the 14 codons that are associated with polymerase activity and substrate binding (Fig. 2) . Some other mutations were found at low frequencies outside DRM sites (Fig.  1) . According to several studies looking for mutations selected by ARVs among CRF01_AE strains compared to subtype B strains, none of theses sites has been shown to be a candidate site for DRM in CRF01_AE strains. 4, 10, 12 Recently, the mutation K238S, especially when accompanied with V106A or V108I, has been associated with resistance to nevirapine (NVP) and is not included in the ANRS and International Aids Society (IAS)-USA lists. 13, 14 The Southeast Asian CRF01_AE consensus carried the K238R mutation (Fig. 2) . One of our strains carried the mutations V108I and K238R. Susceptibility of such strains should be phenotypically investigated to estimate the importance of these mutations. According to the ANRS list, DRM to NNRTIs or NRTIs were rare and were observed only among five HIV-1 strains from pregnant women. One CRF01_AE strain carried the mutation K70R, an NAM, which is known to LY ET AL. 974
FIG. 4.
Comparison of protease consensus (Ͼ50%) sequences of different subtypes from untreated patients. PCONS_CAM is the AE consensus sequence from 135 isolates of our present study; PCONS_TH is the AE consensus sequences of 14 isolates from Thailand; 3 PCONS_VN is the AE consensus sequences of 172 isolates from Vietnam. 5 PCONS_SG is the AE consensus sequences of 35 isolates from Singapore. 4 The rest of the consensus is from sequences of M group (A-K) in the Los Alamos National Laboratory database (http://hiv-web.lanl.gov/content/hiv-db/SUBTYPE_REF/align.html). Residues identical to those of the PCONS_B are indicated by dots. be associated with cross-resistance to NRTIs; three CRF01_AE strains carried the mutation V75M, associated with resistance to stavudine (d4T), and one B strain carried the mutation K101E, associated with resistance to the NNRTIs efavirenz (EFV) and nevirapine (NVP).
The amino acid substitutions of Prot are described in Fig. 3 . When compared with subtype B consensus, mutations of CRF01_AE strains at ANRS DRM sites occurred significantly (Ͼ50%) at positions 13, 35, 36, 41, and 69, while only one occurred significantly outside DRM sites at position 89. Globally, when considering all observed substitutions whatever their frequencies, amino acid substitutions occurred in 41 (41%) of the 99 positions among CRF01_AE strains and 18 (18%) were situated at ANRS DRM positions 10, 13, 20, 24, 33, 35, 36, 41, 45, 46, 62, 63, 69, 74, 77, 82, 88, and 91. The diversity was the highest at position 63 (Fig. 3) . The deduced CRF01_AE Cambodian natural consensus (Ͼ50%) was in agreement with the CRF01_AE consensus observed among isolates from Southeast Asian untreated patients (Fig. 4) . Only the Vietnamese consensus showed one difference at position 16. None of these Cambodian CRF01_AE consensus mutations occurred in a significant site of the protein, except the E35D substitution (located in the active site of the enzyme). The mutation M36I was carried by all non-B consensus while mutations R41K, H69K, and L89M were observed in most of them (Fig. 4) . All our 139 prot sequences had at least one ANRS DRM (minor mutations) but only two strains, belonging to subtype CRF01_AE and from pregnant women, were carrying one major DRM each: M46I associated with resistance to indinavir and ritonavir, and N88D associated with resistance to nelfinavir. In addition, we detected two strains with the treatment-related mutations T74A/S, which has recently been described among CRF01_AE strains and the significance of which is still unclear. 4 The drug resistance-associated mutations we recorded (K70R, V75M, and K101E for rt; M46I and N88D for prot) were observed in independent isolates. Consequently, the prevalence of resistance of HIV-1 isolates to RTIs and PIs among all the untreated patients, the seroconverters, and the pregnant women was 4.9% (7/144), 0% (0/22), and 5.7% (7/122), respectively. These prevalences were of the same level as those expected (0-6%) among untreated subjects in resource-limited countries where HIV treatment has been available (http://www.who.int/3by5/publications/guidelines/en/execsumm.pdf). The target population recommended by WHO for the surveillance of HIV drug resistance included recently infected persons such as pregnant women Ͻ 24 years old during their first pregnancy. Twenty-one pregnant women among our sample fulfilled this case definition and two had strains carrying DRM. The prevalence of resistance to ARVs in this sample was consequently 10% (2/21). However, our sample size is too small compared to the recommended minimum sample number (n ϭ 52) and with our sample size, the estimate of the prevalence in this population with 95% confidence intervals would be too broad (http://www.who.int/3by5/ publications/guidelines/en/execsumm.pdf).
This study provides the first extensive results on the polymorphism of Cambodian HIV-1 strains, using the sequences of rt and prot genes from 144 untreated patients, and the first results on resistance of HIV-1 to ARVs in Cambodia. Although our samples are not representative of the selected populations (VCT consultants and pregnant women), our results indicate that CRF01_AE is still mainly predominant in Cambodia. The prevalence of viral strains bearing drug-resistance mutations is low (Ͻ6%). This situation may change as therapy becomes more widely available and used in the region; then, follow-up studies on HIV resistance to ARVs would be warranted to evaluate their future efficacy. Phenotypic tests should be performed using rt and prot genes from Cambodian CRF01_AE strains that have an original genotype (e.g., consensus rt and prot genes, rt carrying a combination of mutations as V108I and K238R, rt carrying the mutation K43E, prot carrying the mutation T74A/S, etc.) in order to appreciate their role in the resistance or the susceptibility of such HIV-1 strains to RTIs and PIs, respectively.
SEQUENCE DATA
GenBank accession numbers for the sequences reported in the study are DQ013370 to DQ013513 for the partial reverse transcriptase gene, DQ013514 to DQ013652 for the protease gene, and DQ013653 to DQ013791 for C2V3 envelope gene.
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